Clinical data
Trade names Yarvitan
Routes of
By mouth (0.5% solution)
ATCvet code QA08AB90 (WHO)
Pharmacokinetic data
Bioavailability 55–69%
Protein binding >99.9%[1]
Metabolism Extensive liver (sulfoxidation); first pass effect
Biological half-life 6.3 hours (mitratapide), up to 44.7 hours (metabolites)
Excretion Feces (80–90%)[2]
Synonyms Mitratapid; R103757
CAS Number 179602-65-4
PubChem (CID) 213047
ChemSpider 184740
KEGG D05060
Chemical and physical data
Formula C36H41ClN8O4S
Molar mass 717.28 g/mol
3D model (Jmol) Interactive image

Mitratapide is a veterinary drug for the treatment of overweight and obese dogs sold under the brand name Yarvitan. Its mechanism of action involves inhibition of microsomal triglyceride transfer protein (MTP) which is responsible for the absorption of dietary lipids.[3] Clinical study also suggests that mitratapide may help to reverse insulin resistance in dogs.[4]

The drug was developed by Janssen Pharmaceutica and is chemically related to the antifungal drugs such as itraconazole which were also developed by Janssen.

See also


  1. "Yarvitan 5 mg/ml Oral Solution for Dogs. Summary of Product Characteristics" (PDF). Retrieved 27 August 2016.
  2. "Yarvitan (mitratapide). Scientific Discussion" (PDF). Retrieved 27 August 2016.
  3. Mitratapide,
  4. Dobenecker, B; De Bock, M; Engelen, M; Goossens, L; Scholz, A; Kienzle, E (2009). "Effect of mitratapide on body composition, body measurements and glucose tolerance in obese Beagles". Veterinary research communications. 33 (8): 839–47. doi:10.1007/s11259-009-9232-5. PMC 2776940Freely accessible. PMID 19544001.
This article is issued from Wikipedia - version of the 8/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.